Pioneering the Future of Microbiome based Medicine: The Untapped Potential of Acidipropionibacterium
In the rapidly evolving landscape of modern drug discovery, the focus has shifted from chemical synthesis to the intricate biological networks of the human microbiome. Among the diverse microbial candidates being explored for therapeutic purposes, Acidipropionibacterium has emerged as a genus of profound significance. Long recognized for its industrial utility, its role as a "biological factory" capable of modulating host physiology is now being rigorously evaluated in the preclinical stage. As a leading Contract Research Organization (CRO), Creative Biolabs is dedicated to bridging the gap between microbial potential and clinical reality. By providing high-resolution data and sophisticated disease models, we empower biopharmaceutical innovators to harness the specific immunomodulatory and metabolic signatures of these bacteria. Our goal is to transform the understanding of Acidipropionibacterium from a food-grade microorganism into a cornerstone of Live Biotherapeutic Products (LBPs), offering new hope for patients with chronic inflammatory and metabolic disorders.
Overview: The Biology of Acidipropionibacterium
The genus Acidipropionibacterium represents a group of gram-positive, non-spore-forming, anaerobic to aerotolerant bacteria. Formerly grouped within the broader Propionibacterium classification, these "dairy propionibacteria" are distinct from their skin-associated "cutaneous" relatives. Their defining characteristic is their unique fermentative metabolism, primarily the Wood-Werkman cycle, which allows them to convert lactate and various sugars into propionate, acetate, and carbon dioxide.
From a therapeutic perspective, the production of propionate, a key short-chain fatty acid (SCFA), is paramount. Propionate serves as more than just a metabolic byproduct; it is a systemic signaling molecule that interacts with G-protein coupled receptors (GPCRs), specifically GPR41 and GPR43, which are expressed on immune cells and in adipose tissue. This metabolic output, combined with the presence of surface-layer proteins (S-layers) and extracellular vesicles, allows Acidipropionibacterium to communicate directly with the host's immune and endocrine systems.
Explore Our Specialized Strain Portfolios
To deepen your understanding of specific species within this category and their unique therapeutic profiles, please explore our dedicated research sub-pages below.
A well-characterized probiotic candidate known for its robust anti-inflammatory properties, S-layer protein-mediated immunomodulation, and its ability to mitigate colitis and food allergies in preclinical models.
A versatile strain noted for its production of bioactive metabolites and bacteriocins. Research focuses on its role in gut homeostasis and its potential as a biopreservative in therapeutic formulations.
Our Preclinical Research Services
Navigating the transition from "microbe to medicine" requires specialized expertise. Our CRO provides a full suite of services designed specifically for the rigorous evaluation of Acidipropionibacterium-based LBPs.
Genomic and Metabolic Characterization
Whole Genome Sequencing (WGS): We perform high-resolution assembly and annotation to identify essential genes, confirm the absence of virulence factors, and map metabolic pathways for SCFA production.
Metabolomics: Utilizing GC-MS and HPLC, we quantify the production of propionate, acetate, and bioactive vitamins (such as B12 and folate) under various environmental conditions.
Intestinal Barrier Models: We use Caco-2 and HT29 cell lines to measure the impact of the strain on epithelial integrity and bacterial adhesion.
Immunomodulation Assays: Testing the strain's ability to influence cytokine release in human peripheral blood mononuclear cells (PBMCs) or specialized reporter cell lines.
Safety Profiling: Including antibiotic susceptibility testing (AST) and screenings for hemolytic activity to ensure regulatory compliance.
Germ-Free and Gnotobiotic Mice: Enabling researchers to study the strain's effects in a controlled microbial environment.
Disease-Specific Models: We maintain established protocols for DSS-induced colitis, HFD-obesity models, and various xenograft oncology models.
Pharmacokinetics of LBPs: Tracking the survival, colonization duration, and metabolic activity of the strain throughout the GI tract using specialized qPCR and imaging techniques.
Preclinical Products for Your Laboratory
To support in-house R&D, we offer a range of standardized products optimized for microbiome research.
Research-Grade Bacterial Concentrates: High-viability, lyophilized powders of characterized Acidipropionibacterium strains with verified CFU counts.
Optimized Culture Media: Customized formulations designed to maximize the growth and metabolite yield of propionibacteria, reducing your time spent on media optimization.
Metabolic Standards: High-purity propionate and acetate solutions for use in benchmarking and mechanism-of-action studies.
Reference Microbial Consortia: Pre-defined mixtures of commensal bacteria for studying strain-strain interactions and competition.
This product contains high-quality, intact genomic DNA isolated from Acidipropionibacterium acidipropionici Genomic DNA. It is a purified and ready-to-use DNA sample, ideal for a wide range of molecular biology applications, including PCR, qPCR, and Next-Generation Sequencing.
This product contains high-quality, intact genomic DNA isolated from Acidipropionibacterium jensenii Genomic DNA. It is a purified and ready-to-use DNA sample, ideal for a wide range of molecular biology applications, including PCR, qPCR, and Next-Generation Sequencing.
Acidipropionibacterium jensenii DNA Standard product can be used for quantitative research and analysis, assay development, verification, and validation, and laboratory quality control.
Acidipropionibacterium acidipropionici DNA Standard product can be used for quantitative research and analysis, assay development, verification, and validation, and laboratory quality control.
Current preclinical research into Acidipropionibacterium focuses on its ability to act as a localized delivery system for therapeutic metabolites. Unlike traditional drugs that may have systemic side effects, these live biotherapeutics exert their influence precisely where they colonize.
One of the most mature areas of research involves the treatment of ulcerative colitis and Crohn's disease. Acidipropionibacterium strains have demonstrated the ability to:
Promote Mucosal Healing: By stimulating the expression of MUC2 and tight junction proteins, they reinforce the intestinal barrier, preventing "leaky gut" and the translocation of pathogens.
Modulate Cytokine Profiles: Studies show a significant reduction in pro-inflammatory markers such as TNF-α, IL-1β, and IL-6, while simultaneously increasing the production of anti-inflammatory IL-10 through the induction of T-regulatory (Treg) cells.
Research in high-fat diet (HFD) murine models has revealed that Acidipropionibacterium can significantly impact host energy homeostasis. By activating GPR41/43 signaling, the bacteria help regulate glucose tolerance and reduce hepatic inflammation. Furthermore, the propionate produced can stimulate the release of satiety hormones like GLP-1, offering a microbial-based approach to weight management and Type 2 Diabetes.
Emerging evidence suggests that the SCFAs and extracellular vesicles produced by these strains can induce apoptosis in colon cancer cells without harming healthy tissue. This "pro-apoptotic" effect is being researched as a potential adjuvant to standard chemotherapy or immune checkpoint inhibitors, particularly in overcoming tumor resistance to cell death.
4. Food Allergy and Tolerance
By modulating the Th1/Th2 balance in the gut-associated lymphoid tissue, certain strains are being investigated for their ability to prevent or treat food allergies. Preclinical data indicates that early exposure to these bacteria can "train" the immune system toward a state of oral tolerance.
Our Advantages: Why Choose Our CRO?
In a field as complex as live biotherapeutics, the depth of scientific understanding is the primary differentiator. Our company offers several key advantages:
Microbiome Specialization
We are not a generalist CRO. Our infrastructure, including anaerobic workbenches and specialized bioreactors, is dedicated to the unique needs of anaerobic bacteria.
Integrated Bioinformatic Pipelines
We provide more than just raw sequencing data; our reports include functional interpretations, correlating microbial changes with host phenotypic outcomes.
Regulatory-Ready Data
Our study designs are aligned with FDA and EMA guidelines for IND-enabling preclinical studies, ensuring your data package stands up to regulatory scrutiny.
Tailored Study Designs
We understand that every strain is different. Our scientists work closely with you to design bespoke experiments that highlight the unique value proposition of your specific LBP candidate.
Forging the Path to Clinical Success
The journey of Acidipropionibacterium from the dairy vat to the pharmacy shelf is a testament to the power of scientific re-discovery. As we uncover the intricate ways in which these bacteria interact with our biology, through the production of SCFAs, the modulation of immune cells, and the stabilization of the gut barrier, we move closer to a new era of precision medicine. At our CRO, we are more than just a service provider; we are your strategic partner in this journey. We believe that with the right data, the right models, and a shared commitment to excellence, the potential of live biotherapeutics is limitless.
We invite you to reach out to our scientific team to discuss your current challenges and goals. Whether you are identifying your first lead candidate or preparing for an IND submission, we provide the technical rigor and innovative spirit required to bring your vision to life. Let us work together to harness the power of Acidipropionibacterium and redefine what is possible in the treatment of human disease.
Is Acidipropionibacterium safe for use in human therapeutics?
Many species have a long history of safe use in food (GRAS status). However, for use as a drug (LBP), they must undergo rigorous safety assessments, including genomic screening for resistance genes and in vivo toxicity testing, all of which we provide.
How do you ensure the strain survives the journey through the stomach?
We perform simulated gastric fluid (SGF) and bile salt tolerance testing. Additionally, we offer formulation and microencapsulation services to enhance the survival and targeted delivery of the bacteria.
Can these bacteria be genetically modified to deliver specific drugs?
Yes. Acidipropionibacterium is an excellent candidate for synthetic biology applications. We can assist in characterizing the performance and stability of engineered strains in our disease models.
What is the typical timeline for a preclinical efficacy study?
Depending on the model (e.g., a 7-day colitis model vs. a 12-week obesity study), timelines vary. However, our integrated approach typically streamlines the process from strain characterization to final reporting within 4 to 6 months.
Online Inquiry
For Research Use Only. Not intended for use in
food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
